Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analyses for control and nicotinamide treated TNBC cells

ABSTRACT: RNA-seq analyses for control and nicotinamide treated TNBC cells

PROVIDER: PRJNA723560 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14294811_1.fastq.gz	Fastqsanger.gz
	SRR14294811_2.fastq.gz	Fastqsanger.gz
	SRR14294812_1.fastq.gz	Fastqsanger.gz
	SRR14294812_2.fastq.gz	Fastqsanger.gz
	SRR14294813_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

RNA-seq analyses for control and nicotinamide treated TNBC cells

Project description:In this study, we investigated how nicotinamide (NAM) affects cellular metabolism in TNBC cells and also such altered cellular metabolism by NAM is linked to cytotoxic functions through an integrated analysis of proteome and transcriptome data generated from three different TNBC cell lines, BT20, MB468, and MB231. By analyzing mRNA-seq data from control and NAM treated TNBC cells (3 replicates in each of 3 cell lines), we identified differentially expressed genes (DEGs), and associated cellular process. The up-regulated genes were associated with the processes related to cell death (programmed cell death, autophagy, and apoptotic mitochondrial changes) and mitochondria (organization, pH reduction/oxidation-reduction/NADP metabolism, response to starvation, respiratory chain, and lipid/oxoacid metabolism). On the other hand, the processes related to immune response (NF-kB and MAPK signaling, cell adhesion/migration, and response to cytokine) and cell proliferation were down-regulated consistently in the three TNBC cells.

2021-04-22 | GSE172494 | GEO

In-depth proteomics analysis of nicotinamide responses in triple negative breast cancer cells

Project description:Triple negative breast cancer (TNBC) is characterized by an aggressive biologic behavior without specific targeted agent. Nicotinamide has recently been proven as a novel therapeutic agent for skin tumors in ONTRAC trial. Here we performed in-depth proteomes to characterize network of molecular interactions in TNBC cells treated by nicotinamide. Proteome profiles identified nicotinamide drives significant functional alterations related to major cellular pathways, including cell cycle, DNA replication, apoptosis and DNA damage repair. We further elaborated global signaling networks of molecular events with nicotinamide inducible expression changes in protein levels. This approach reveals that nicotinamide treatment rewires signaling networks towards dysfunction of DNA damage repair and away form a pro-growth state in TNBC. To our knowledge, our results of high resolution signaling network interactions provides the first evidence to comprehensively support the hypothesis of nicotinamide as a novel therapeutic agent in TNBC.

2017-06-20 | PXD005304 | Pride

Human TNBC Cells 48h Treatment with OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 48 hours with OTSSp167 MELK Inhibitor and control (DMSO)

2017-05-01 | GSE68652 | GEO

Human TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO)

2017-05-01 | GSE68692 | GEO

Human TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO)

2017-05-01 | GSE68691 | GEO

Human TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO)

2017-05-01 | GSE71027 | GEO

Human TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO)

2017-05-01 | GSE71026 | GEO

Human TNBC Cells 48h Treatment with OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 48 hours with OTSSp167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 48h. Two biological replicates, one per array, with a dye swap (technical replicate).

2017-05-01 | E-GEOD-68652 | biostudies-arrayexpress

Human TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 45nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).

2017-05-01 | E-GEOD-68692 | biostudies-arrayexpress

Human TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control

Project description:Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).

2017-05-01 | E-GEOD-68691 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data